Lance Scott

Head of Marketing

VDyne

Mar 2026 - Current (3 months)

Serve as a key commercial leader in a fast-growing startup developing breakthrough tricuspid valve replacement (TTVR) therapies. Responsible for building and executing the company’s global marketing strategy from early clinical stages through commercialization. As a member of the leadership team, help shape market development as well as collaborate to define the clinical and economic narrative for VDYNE TTVR and drive adoption.

C

Chief Executive Officer

Concordia Life Sciences LLC

Jul 2025 - Current (11 months)

Concordia Life Sciences is a consulting firm that partners with pharmaceutical, medical device, and digital health organizations to solve complex strategic, operational, and commercial challenges. Concordia combines deep industry expertise and extensive experience to support clients across the full product lifecycle—from early development and market access to commercialization and post-launch optimization. We work collaboratively with clients to deliver practical, high-impact solutions that improve patient outcomes while driving sustainable growth.

Vice President Marketing

Imperative Care

Oct 2021 - Current (4 years 8 months)

Lead marketing for Imperative Care's Vascular business, that is redefining peripheral vascular thrombus management. Responsibilities include company communication, business unit branding, upstream and downstream product management, go-to-market strategy, training and medical education.

Senior Vice President Marketing

Imperative Care

Oct 2021 - Jun 2025 (3 years 9 months)

Lead marketing for Imperative Care's Vascular business, that is redefining peripheral vascular thrombus management. Responsibilities include company communication, business unit branding, upstream and downstream product management, go-to-market strategy, training and medical education.

Chief Commercial Officer

HeartFlow Inc

Jan 2019 - Sep 2021 (2 years 9 months)

Led the global commercial business with responsibility for sales, marketing, customer success and product. HeartFlow, Inc. is a digital health company uniquely positioned at the intersection of advanced artificial intelligence and healthcare to transform how heart disease is diagnosed and treated. The non-invasive HeartFlow FFRct Analysis leverages deep learning to create a personalized 3D model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients.

Vice President, U.S. Sales & Marketing, Surgical Heart Valve Therapy

Edwards Lifesciences

Nov 2017 - Jan 2019 (1 year 3 months)

Led the U.S. commercial organization (Sales & Marketing) for Edwards surgical portfolio which includes Edwards INTUITY Elite, Edwards INPIRIS, Edwards Magna Ease aortic valves as well as Edwards Magna Mitral Ease valve along with a range of best-in-class repair solutions.

Chief Executive Officer

Zephyr Health

Dec 2015 - Oct 2017 (1 year 11 months)

Zephyr Health is the only Insights-as-a-Service solution - built specifically for Life Sciences - harnessing the power of global healthcare data to address critical business and patient needs. Our mission is to organize and visualize global health data to help our customers connect their therapies to people in need. Lance Scott is the Chief Executive Officer driving the company's strategy and operations for growth with a customer-centric focus given his deep, global expertise in Pharmaceuticals, Medical Device, Primary Care and Specialty Pharma.

Divisional Vice President, General Manager

Abbott Vascular

Feb 2012 - Nov 2015 (3 years 10 months)

Directed $2.3 billion global coronary business unit including marketing, new product planning, portfolio strategy, and market access. • Portfolio products: Absorb, Xience V (drug eluting stent), Xience PRO, Xience PRIME (drug eluting stent), Xience Xpedition, Vision (bare metal stent), TREK BDC, coronary guidewire portfolio including Balance Middle Weight, Pilot, and Progress

Divisional Vice President Global Marketing

Abbott Vascular

May 2008 - Jan 2012 (3 years 9 months)

Led product planning and launch for $2.6 billion global product line, comprehensive of research & development, new product and market development, global marketing and portfolio strategy and promotional activities for on-market products. • Portfolio Coronary products: ABSORB, Xience V, Xience PRIME, Vision, TREK BDC, coronary guidewires. • Portfolio Endovascular products: carotids (Acculink / Xact), vessel closure (ProGlide, ProStar, Starclose), peripheral products (Armada balloons, Versacore wires, Hercules renal stents).

D

Divisional Vice President, Specialty Pharmaceuticals (U.S.)

Jul 2007 - May 2008 (11 months)

Led $2.8 billion U.S. specialty pharmaceutical portfolio with responsibility for marketing and sales for the following therapeutic areas: Neuroscience (Depakote), HIV (Kaletra / Norvir), Renal (Zemplar), Anesthesia (Ultane), Pain (pipeline products), and Oncology (pipeline products). • Annual revenue responsibility of with margin contribution of $1.7 billion. Managed operational budget of $540 million with headcount of 1,500.

D

Divisional Vice President, HIV (U.S.)

Apr 2007 - Jun 2007 (3 months)

Managed sales, marketing, community engagement and education for U.S. HIV business including market-leading protease inhibitors Kaletra and Norvir. Held leadership position on Therapeutic Executive Committee (TEC) guiding development programs for Abbott’s hepatitis C (HCV) future portfolio.

D

Divisional Vice President, KOS Integration

Dec 2006 - Mar 2007 (4 months)

Managed comprehensive integration of KOS pharmaceutical ($3 billion acquisition) which resulted in the addition of Niaspan to Abbott’s dyslipidemia portfolio.

Divisional Vice President, Primary Care Sales (U.S.)

Abbott Vascular

Oct 2005 - Nov 2006 (1 year 2 months)

Responsible for $2.8 billion, 2,500 employee U.S. primary care sales organization. Piloted group practice account strategy and established dedicated cardiovascular specialty sales team. Product portfolio: TriCor, Niaspan, Synthroid, and Omnicef

National Sales Director, Primary Care Sales (U.S.)

Abbott Vascular

Apr 2005 - Sep 2005 (6 months)

Led day-to-day operations of the US Primary Care Sales organization including sales force alignment / deployment, development of call plan / allocation of sales force selling capacity, and design of incentive plans.

A

Area Sales Director – Primary Care (Southern Area)

Sep 2003 - Mar 2005 (1 year 7 months)

Directed a sales team of 429 representatives in 11 states (5 regions, 45 districts) for all primary care products. • Product portfolio: TriCor, Biaxin XL, Omnicef, Tarka, Synthroid, Meridia

R

Regional Sales Management

Jan 2000 - Aug 2003 (3 years 8 months)

Managed sales and a team of up to 100 representatives in various regions from the Central West to the Southern and Northern Regions, covering up to 14 states. Helped create new cardiovascular sales force (CVR) to sell to office-based primary care physicians as well as cardiologists, endocrinologists, and nephrologists. • Product portfolio: Antihypertensive agents (Mavik & Tarka), TriCor (lipids) and Flomax (BPH)

P

Product Management & Medical Liaison Management

Oct 1996 - Dec 1999 (3 years 3 months)

Led various Brand Management teams, coordinated efforts for NDA and sNDA filings and established plans for market introduction. * Product portfolio: TriCor, Ditropan XL (during ALZA co-promotion initiative), Gengraf (transplant), Zyflo (asthma) in U.S. market

District Sales Manager

Abbott Vascular

Sep 1994 - Sep 1996 (2 years 1 month)

Managed South Central District and Dallas district sales and participated in the creation of a new sales organization of specialty representatives calling on key academic centers and teaching hospitals in a 5-state area. * Product responsibilities: Biaxin, Biaxin OS, Prevacid, Hytrin, and Norvir

About

Detail

Timeline

Résumé